November 2, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2607326

TAVR in Patients with Moderate Aortic Stenosis with At-Risk Features.

Listen to this summary

Current guidelines recommend only clinical surveillance for patients with moderate aortic stenosis, but it is unknown whether transcatheter aortic-valve replacement (TAVR) improves outcomes in those with at-risk features. In this international randomized trial of 744 patients, transfemoral TAVR was superior to surveillance for reducing death or heart-failure events at 2 years (16.7% vs. 23.9%, risk difference -7.2 percentage points, P = 0.02), driven mainly by fewer heart-failure events, with no meaningful difference in all-cause mortality.

Philippe Généreux, Raj R Makkar, Philippe Pibarot, Jeroen J Bax, Brian R Lindman, Kamran Muhammad, J Bradley Oldemeyer, Mark Pirwitz, Colin M Barker, Vinod H Thourani, Pradeep K Yadav, Roberto Rodriguez, Justin Strote, Rahul Sakhuja, Ramzi Khalil, Rahul Sharma, Adnan Chhatriwalla, Jacob M Mishell, Biswajit Kar, Sameer Gafoor, Joseph Walsh, Daniel Spoon, Andrew Frutkin, Andrei Pop, Nicolas M Van Mieghem, Ruby Satpathy, Kenji Ando, Joseph Montarello, John Webb, Sreekanth Vemulapalli, David J Cohen, Aakriti Gupta, Brandon Park, Heather Prince, Philipp Blanke, Michael Mack, Martin B Leon

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play